GlobeNewswire Inc.T3·3mo ago
CPRX Catalyst Pharmaceutical Inc.
XNAS
31.49
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CPRX
$31.49
—
Key stats
$31.49
- 52-Week Range
- $20.66 – $32.56
- YTD
- +36.03%
- Straddle Price
- $8.75
- P/C Vol Ratio
- 0.00
- Market Cap
- $3.9B
- Open
- $31.48
- Day Range
- $31.48 – $31.50
- Volume
- 15,451,138
- Prev Close
- $31.48
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.56% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.06% (VRP-adj) |
| WACC | 9.96% |
| Volatility Risk Premium | +17.5pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 25.3% |
| Rev. Growth (YoY, DCF input) | +1.9% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.02 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.2B |
| Return on Equity (TTM) | 21.9% |
| Book / Price | 25.3% |
| Gross Margin (TTM) | 86.0% |
| FCF Margin (TTM) | 34.9% |
| Debt / Equity | 0.00 |
| Quality Score | 5/6 — high quality (12y DCF) |
| Market-Implied Growth | +4.5% (reverse-DCF on current price) |
| SMA 50 | $31.21 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $31.44 |
| Bollinger Width / SMA20 | 1.8% (drives anchor stability) |
| Net Debt | $-0.8B |
| Market Cap | $4B |
Peers used for multiples: ALKS, BTSG, CORT, KRYS, MOH, PTCT, PTGX, TGTX
60-Day Conviction
76%
20-Day Fair Value
≈ by Aug 13, 2026
$33.02
α +4.9%
rank 61%
conviction
75%
40-Day Fair Value
≈ by Sep 11, 2026
$33.33
α +5.8%
rank 79%
conviction
64%
60-Day Fair Value
≈ by Oct 12, 2026
$35.31
α +12.1%
rank 75%
conviction
76%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $27.65 | 23% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $92.42 | 10% | median 52.1× · 6 peers |
| Peer EV/EBITDA | $109.93 | 10% | median 42.4× · 5 peers |
| Peer P/B | $66.80 | 2% | median 8.4× · 7 peers |
| Peer P/S | $48.20 | 7% | median 10.1× · 8 peers |
| Market Anchor (SMA50) | $31.21 | 47% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-07-15 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $3.9B
- Employees
- 182
- List Date
- 2006-11-08
- CIK
- 0001369568
- Headquarters
- Coral Gables, FL
- Homepage
- https://www.catalystpharma.com
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including cl…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
Insufficient price history — listed 7288 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $31.44
SMA 50: $31.21
SMA 200: $25.35
Current: $31.49
EMA 12: $31.46
EMA 26: $31.30
MACD: 0.1600 | Signal: -0.0537
BULLISH
ADX (14): 64.24
STRONG TREND
+DI: 34.59
−DI: 6.43
Momentum Oscillators
RSI (14): 70.18
OVERBOUGHT
Stoch %K: 83.38
Stoch %D: 81.00
Williams %R: -13.04
Volume & Volatility
BB Upper: $31.53
BB Lower: $31.35
NEUTRAL
OBV: 74,972,483
Vol SMA 20: 2,830,695
Vol ROC: 781.49%
ATR: $0.08
True Range: $0.02
HV 20: 1.5%
HV 30: 1.4%
HV 60: 26.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-07-16T00:00:00 – 2026-07-14T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: CPRX
Executive Summary: BULLISH (Confidence Level: 6/10)
Key Drivers and Primary Risks:
- Bullish momentum signals from MACD and Stochastic Oscillators
- Neutral RSI reading indicates market is not overbought or oversold
- Moderate volatility, following market trends
- Recent news sentiment neutral, awaiting earnings release
Technical Analysis: Trend Direction:
- Short-term: Uptrend (SMA 20 above current price)
- Medium-term: Sideways consolidation (SMA 50 and SMA 200 in alignment)
- Long-term: Uptrend (SMA 200 above SMA 50)
Support/Resistance Levels:
- Key resistance level at $21.43 (upper Bollinger Band)
- Support levels at $19.18 (lower Bollinger Band) and $20.31 (SMA 20)
Momentum Signals:
- MACD: Bullish, with a signal line crossover above the zero line
- RSI: Neutral (51.69), indicating no strong buying or selling pressure
Volume Analysis:
- Volume SMA 20 declining, suggesting reduced institutional interest
- On-Balance Volume (OBV) negative, indicating selling pressure
- Volume Rate of Change: -3.47%, indicating a moderate decline in trading activity
News & Sentiment Analysis: Recent Headlines Summary: No recent news available
Sentiment Assessment: Neutral
Catalyst Identification:
- Upcoming earnings release on 2025-11-05, potentially impacting stock price
- Recent history of mixed earnings surprises and guidance changes
Market Narrative: The market narrative is neutral, with no strong sentiment or trends driving the stock price. The technical analysis suggests a possible uptrend, but the absence of recent news and moderate volatility may limit the potential for significant price movements.
Risk & Volatility Assessment: Beta Interpretation:
- Beta 0.87 indicates moderate risk relative to the market
- Stock generally follows market trends with limited independent movement
Volatility Regime: Current vs historical volatility levels: Moderate, following market trends
Options Market Signals:
- IV Rank: Low (19.4%), suggesting historically low volatility
- Put/Call Volume Ratio: Neutral (1.04), indicating balanced sentiment
- Options market pricing a $3.20 move by expiration
Downside Protection: Support levels at $19.18 (lower Bollinger Band) and $20.31 (SMA 20)
Market Context & Positioning: Sector Performance: Relative strength vs sector/market: Neutral
Institutional Activity: Volume patterns suggesting institutional interest have declined, indicating reduced buying pressure
Correlation Analysis: The stock moves relatively in tandem with the market (R-squared interpretation), indicating a moderate correlation
Relative Valuation: Position within trading range: Bullish, as the stock price remains above key support levels
Key Levels & Action Items: Critical Price Levels:
- Resistance at $21.43 (upper Bollinger Band)
- Support levels at $19.18 (lower Bollinger Band) and $20.31 (SMA 20)
Breakout/Breakdown Levels: No specific levels identified, as the stock price remains within a moderate trading range
Time-Sensitive Catalysts:
- Upcoming earnings release on 2025-11-05
- Potential for significant price movements based on earnings surprise or guidance changes
Risk Management: Stop-loss levels: $19.18 (lower Bollinger Band) and $20.31 (SMA 20) Position sizing considerations: Moderate, as the stock price remains within a trading range
Generated
News
All CPRX news →
BenzingaT3·5mo ago
BenzingaT3·5mo ago
GlobeNewswire Inc.T3·5mo ago
Investing.comT3·7mo ago
The Motley FoolT3·9mo ago
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·14mo ago
GlobeNewswire Inc.T3·19mo ago
Showing 1–10 of 50
Page 1 of 5
CPRX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $8.75
7-DTE Move: $4.00
Days to Exp: 38 (2026-08-21)
Options Flow
Call Volume: 267
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 84
Put OI: 0
P/C OI: —
Total OI: 84
ATM Options Pricing
ATM Call: $1.25
ATM Put: $7.50
Call %: 4.0%
Put %: 23.8%
Chain Summary
Chain Volume: 1,862
Chain OI: 10,080
Last Updated: 7/14/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 63rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
63%
vs own history
GEX tilt
+0.42
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 6k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Jul 14 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Jul 14 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$8.75Jul 14
Beta Analysis
Insufficient price history — listed 7288 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.
Notable investors who own CPRX
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $67.1M | #245 of 3138 | -9.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $33.6M | #830 of 3716 | +39.3% | 13F | |
| Soros Fund Management Family office George Soros, Robert Soros, Jonathan Soros | $10.8M | #129 of 251 | new | 13F | |
| Point72 Hedge fund Steve Cohen | $5.5M | #951 of 1945 | -58.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $2.7M | #2618 of 6285 | -85.3% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $620K | #1978 of 4729 | +0.1% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CPRX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 127,198,699 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$1.67M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Schonfeld Strategic Advisors LLC | $785.75K | 47.17% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $361.44K | 21.70% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $282.87K | 16.98% | 2026-06-30 |
| 4 | SUMMIT SECURITIES GROUP LLC | $172.87K | 10.38% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $47.15K | 2.83% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $15.53K | 0.93% | 2026-06-30 |
2 filers$2.61M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.61M | 100.00% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $0 | 0.00% | 2026-06-30 |
CPRX Insider Trading (Form 4)
Latest: 2026-07-17Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-17 | Molly Harper | Director | Disp (D) | −3,694 | $31.50 | -$116.4K | EDGAR |
| 2026-07-17 | Richard J Daly | President and CEO | Disp (D) | −271,266 | $31.50 | -$8.54M | EDGAR |
| 2026-07-17 | William T. Andrews | Chief Medical Officer | Disp (D) | −2,309 | $31.50 | -$72.7K | EDGAR |
| 2026-07-17 | Donald A Denkhaus | Director | Disp (D) | −498,773 | $31.50 | -$15.71M | EDGAR |
| 2026-07-17 | Steve Miller | Chief Op. & Scientific Officer | Disp (D) | −1,093,803 | $31.50 | -$34.45M | EDGAR |
| 2026-07-17 | Gregg Russo | Chief HR Officer | Disp (D) | −476 | $31.50 | -$15.0K | EDGAR |
| 2026-07-17 | David S Tierney | Director | Disp (D) | −383,314 | $31.50 | -$12.07M | EDGAR |
| 2026-07-17 | Preethi Sundaram | Chief Strategy Officer | Disp (D) | −54,804 | $31.50 | -$1.73M | EDGAR |
| 2026-07-17 | Jeffrey Del Carmen | Chief Commercial Officer | Disp (D) | −14,337 | $31.50 | -$451.6K | EDGAR |
| 2026-07-17 | Michael Wayne Kalb | Chief Financial Officer | Disp (D) | −13,665 | $31.50 | -$430.4K | EDGAR |
| 2026-07-17 | Tamar Thompson | Director | Disp (D) | −3,773 | $31.50 | -$118.8K | EDGAR |
| 2026-07-17 | Daniel J. Curran | Director | Disp (D) | −63,583 RSU | — | EDGAR | |
| 2026-07-17 | Patrick J McEnany | Director | Disp (D) | −4,171,559 | $31.50 | -$131.40M | EDGAR |
| 2026-07-17 | Brian Elsbernd | Chief Legal Officer | Disp (D) | −242,501 | $31.50 | -$7.64M | EDGAR |
| 2026-06-05 | William T. Andrews | Chief Medical Officer | Mixed | +2,309 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CPRX Insider Holdings
3 insiders · @ $31.49
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Charles B O'Keeffe | Director | 732,470 | $23.07M | $1.91M | 69 | 2025-02-19 |
| 2 | Patrick J McEnany | Director | 145,922 | $4.60M | -$51.60M | 90 | 2026-07-17 |
| 3 | Gary Ingenito | Chief Med. & Reg. Officer | 68,873 | $2.17M | -$20.55M | 33 | 2025-05-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CPRX Board & Officers
As of SEC filings through Jul 17, 2026Officers 1
- Gary Ingenito · Chief Med. & Reg. Officer · listed since Dec 2023
Changes in the last 10 years (36)
| Jul 17, 2026 | William T. Andrews reported in an SEC filing no longer being Chief Medical Officer |
| Jul 17, 2026 | Tamar Thompson reported in an SEC filing no longer being a director |
| Jul 17, 2026 | Steve Miller reported in an SEC filing no longer being Chief Op. & Scientific Officer |
| Jul 17, 2026 | Richard J Daly reported in an SEC filing no longer being a director |
| Jul 17, 2026 | Richard J Daly reported in an SEC filing no longer being President and CEO |
| Jul 17, 2026 | Preethi Sundaram reported in an SEC filing no longer being Chief Strategy Officer |
| Jul 17, 2026 | Patrick J McEnany reported in an SEC filing no longer being a director |
| Jul 17, 2026 | Molly Harper reported in an SEC filing no longer being a director |
| Jul 17, 2026 | Michael Wayne Kalb reported in an SEC filing no longer being Executive Vice President & CFO |
| Jul 17, 2026 | Jeffrey Del Carmen reported in an SEC filing no longer being Chief Commercial Officer |
| Jul 17, 2026 | Gregg Russo reported in an SEC filing no longer being Chief HR Officer |
| Jul 17, 2026 | Donald A Denkhaus reported in an SEC filing no longer being a director |
| Jul 17, 2026 | David S Tierney reported in an SEC filing no longer being a director |
| Jul 17, 2026 | Daniel J. Curran reported in an SEC filing no longer being a director |
| Jul 17, 2026 | Brian Elsbernd reported in an SEC filing no longer being Chief Compliance/Legal Officer |
| Aug 1, 2025 | Daniel J. Curran became a director |
| Jun 2, 2025 | William T. Andrews became Chief Medical Officer |
| Feb 13, 2025 | Gregg Russo became Chief HR Officer |
| Jan 3, 2024 | Richard J Daly first listed as President and CEO in an SEC filing |
| Jan 3, 2024 | Patrick J McEnany no longer listed as President and CEO in SEC filings |
| Jan 1, 2024 | Michael Wayne Kalb became Executive Vice President & CFO |
| Dec 8, 2023 | Gary Ingenito listed as Chief Med. & Reg. Officer (previously Chief Medical Officer) in SEC filings |
| Dec 7, 2023 | Steve Miller listed as Chief Op. & Scientific Officer (previously Chief Operating Officer) in SEC filings |
| Dec 1, 2023 | The company announced the departure of Alicia Grande as VP, Treasurer and CFO in an SEC filing |
| May 25, 2023 | Tamar Thompson became a director |
| Mar 29, 2023 | The company announced the departure of Philip H Coelho from the board in an SEC filing |
| Dec 8, 2022 | Gary Ingenito listed as Chief Medical Officer (previously Chief Medical & Reg. Officer) in SEC filings |
| Feb 16, 2022 | Preethi Sundaram listed as Chief Strategy Officer (previously Chief Product Devel. Officer) in SEC filings |
| Dec 30, 2021 | Gary Ingenito listed as Chief Medical & Reg. Officer (previously Chief Medical Officer) in SEC filings |
| Dec 8, 2021 | Gary Ingenito first listed as Chief Medical Officer in an SEC filing |
| Jul 6, 2021 | Preethi Sundaram became Chief Product Devel. Officer |
| Jun 29, 2021 | Molly Harper became a director |
| Jan 4, 2021 | Gary Ingenito reported in an SEC filing no longer being Chief Medical Officer |
| Jun 23, 2020 | Jeffrey Del Carmen became Chief Commercial Officer |
| Dec 27, 2018 | Brian Elsbernd became Chief Compliance/Legal Officer |
| Jun 13, 2018 | Daniel Brennan became Chief Commercial Officer |
Not reported recently (2)
- Charles B O'Keeffe · Last reported as a director in an SEC filing dated Feb 19, 2025
- Daniel Brennan · Last reported as Chief Commercial Officer in an SEC filing dated Dec 4, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CPRX Proposed Insider Sales (Form 144)
Latest: 2025-12-12
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-12-12 | Harper Molly | Director | 26,746 | $621.9K | 2025-12-12 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-11-26 | Del Carmen Jeffrey | Officer | 10,983 | $256.2K | 2025-11-26 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-11-12 | Elsbernd Brian | Officer | 40,000 | $907.9K | 2025-11-12 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-09-08 | Elsbernd Brian | Officer | 30,000 | $609.0K | 2025-09-08 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-09-04 | Elsbernd Brian | Officer | 30,000 | $585.6K | 2025-09-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-09-03 | Elsbernd Brian | Officer | 20,000 | $401.5K | 2025-09-03 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-08-27 | Tierney David S | Director | 26,000 | $525.1K | 2025-08-27 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-08-26 | Miller Steve | Officer | 115,000 | $2.33M | 2025-08-26 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-08-26 | Daly Richard J | Officer, Director | 22,970 | $473.6K | 2025-08-26 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-06-11 | Sundaram Preethi | Officer | 1,600 | $42.3K | 2025-06-11 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
30 ETFs hold CPRX
25 shown · $53.70M total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.08% | $17.4M | — | 2026-05-31 |
| 2 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 0.29% | $9.9M | — | 2026-04-30 |
| 3 | PSC Principal U.S. Small-Cap ETF | Nport | 0.16% | $3.8M | — | 2026-06-30 |
| 4 | CLSE Convergence Long/Short Equity ETF | Nport | 0.51% | $3.1M | — | 2026-05-31 |
| 5 | SFLO VictoryShares Small Cap Free Cash Flow ETF | Nport | 0.43% | $2.6M | — | 2026-06-30 |
| 6 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.30% | $2.2M | — | 2026-06-30 |
| 7 | RNIN Bushido Capital US SMID Cap Equity ETF | Nport | 1.36% | $2.1M | — | 2026-04-30 |
| 8 | ECML Euclidean Fundamental Value ETF | Nport | 1.59% | $2.1M | — | 2026-06-30 |
| 9 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $2.0M | — | 2026-05-31 |
| 10 | ARB AltShares Merger Arbitrage ETF | Nport | 1.84% | $1.9M | — | 2026-05-31 |
| 11 | SIXS ETC 6 Meridian Small Cap Equity ETF | Nport | 1.43% | $1.8M | — | 2026-05-31 |
| 12 | TPSC Timothy Plan US Small Cap Core ETF | Nport | 0.27% | $957,515 | — | 2026-06-30 |
| 13 | VAMO Cambria Value and Momentum ETF | Nport | 1.01% | $841,593 | — | 2026-04-30 |
| 14 | BFOR Barrons 400 ETF | Nport | 0.31% | $668,135 | — | 2026-05-31 |
| 15 | QVMS Invesco S&P SmallCap 600 QVM Multi-Factor ETF | Nport | 0.22% | $527,225 | — | 2026-05-31 |
| 16 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Nport | 0.13% | $376,821 | — | 2026-05-31 |
| 17 | EVNT AltShares Event-Driven ETF | Nport | 2.52% | $308,459 | — | 2026-05-31 |
| 18 | CAFG Pacer US Small Cap Cash Cows Growth Leaders ETF | Nport | 1.16% | $263,325 | — | 2026-04-30 |
| 19 | IVSS Applied Finance IVS US SMID ETF | Nport | 0.86% | $231,953 | — | 2026-06-30 |
| 20 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.06% | $159,991 | — | 2026-05-31 |
| 21 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.02% | $144,064 | — | 2026-05-31 |
| 22 | GVLU Gotham 1000 Value ETF | Nport | 0.06% | $139,926 | — | 2026-06-30 |
| 23 | STXK Strive Small-Cap ETF | Nport | 0.15% | $128,014 | — | 2026-06-30 |
| 24 | SXQG ETC 6 Meridian Quality Growth ETF | Nport | 0.08% | $51,654 | — | 2026-05-31 |
| 25 | LITL Simplify Piper Sandler US Small-Cap PLUS Income ETF | Nport | 0.62% | $42,776 | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$1.74
TTM Revenue
$596.96M
TTM Net Income
$221.32M
TTM Op. Cash Flow
$208.21M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $149.39M | $63.73M | $0.50 | $59.59M |
| Q4 '25 | 2025-12-31 | $152.61M | $52.70M | $0.41 | $44.89M |
| Q3 '25 | 2025-09-30 | $148.39M | $52.78M | $0.42 | $32.44M |
| Q2 '25 | 2025-06-30 | $146.56M | $52.11M | $0.41 | $71.30M |
| Q1 '25 | 2025-03-31 | $141.42M | $56.74M | $0.45 | $60.04M |
| Q4 '24 | 2024-12-31 | $141.82M | $55.94M | $0.44 | $70.88M |
| Q3 '24 | 2024-09-30 | $128.69M | $43.88M | $0.35 | $72.87M |
| Q2 '24 | 2024-06-30 | $122.71M | $40.79M | $0.33 | $64.14M |
| Q1 '24 | 2024-03-31 | $98.51M | $23.27M | $0.19 | $31.93M |
| Q4 '23 | 2023-12-31 | $110.57M | $34.84M | $0.31 | $55.65M |
| Q3 '23 | 2023-09-30 | $102.69M | $-30.76M | $-0.29 | $45.13M |
| Q2 '23 | 2023-06-30 | $99.58M | $37.76M | $0.33 | $30.75M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
0.00
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
21.9%
ROA
19.3%
Div Yield
0.00%
FCF Yield
—
Debt/Equity
0.00
Current Ratio
—
Market Cap
$0.00
as of 2026-07-15
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
340.26K
SI % of Float
0.29%
Days to Cover
1.00
Short Vol Ratio
42.4%
Free Float
115.58M
Float %
94.4%
Short interest 2026-07-15 • Short volume 2026-07-14 • Float 2026-05-27